Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)
Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Yohann Loriot(Institut Gustave Roussy), Mary A. Tagliaferri(Nektar Therapeutics (United States)), Konstantin Penkov, Tianhua Wang(Nektar Therapeutics (United States)), Daniel Castellano(Universidad Complutense de Madrid), Vadim S. Koshkin(UCSF Helen Diller Family Comprehensive Cancer Center), Riikka Järvinen, Srikala S. Sridhar(Princess Margaret Cancer Centre), Robert Huddart(Institute of Cancer Research), Mehmet Asım Bilen(Emory Healthcare), Shermeen Poushnejad(Nektar Therapeutics (United States)), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Arjun Vasant Balar(NYU Langone Health), Hakan Harputluoğlu(Inonu University), Anila Qureshi(Bristol-Myers Squibb (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Avivit Peer(Technion – Israel Institute of Technology), Aleksandr Vasiliev(Russian Railways)
Cited by 0
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k